Hormone Therapy in Postmenopausal Women

Introduction to Hormone Therapy

The American College of Physicians recommends estrogen-only therapy for women who have undergone hysterectomy, as the primary purpose of progesterone is to protect the endometrium from estrogen-stimulated hyperplasia and potential cancer, which is unnecessary without a uterus 1, 2

The FDA withdrew approval of 17-alpha hydroxyprogesterone caproate in 2023, highlighting evolving understanding of progestin safety and efficacy 1
The American College of Physicians recommends considering a combined estrogen-progestin regimen for women with an intact uterus and estrogen-only options for women post-hysterectomy 2

For women without a uterus requiring hormone therapy, estrogen-only therapy is recommended as first-line treatment for menopausal symptoms, and progesterone should be avoided as it provides no endometrial protection benefit and may introduce unnecessary risks 1, 2
The U.S. Preventive Services Task Force concludes that the benefits of hormone therapy for chronic disease prevention are unlikely to outweigh harms for most postmenopausal women 2
The American College of Physicians recommends using combined oral contraceptives (COCs) for contraception and osteoporosis prevention, but notes they are not FDA-approved for menopause management 2
The American College of Physicians recommends continuing COCs until age 50-51, then transitioning to traditional hormone replacement therapy if needed, and prescribing at the lowest effective dose for the shortest duration needed 2

The American College of Physicians recommends monitoring for increased risk of venous thromboembolism, stroke (especially in women with hypertension), and gallbladder disease when using COCs for menopause management 2
The American College of Obstetricians and Gynecologists suggests assessing for standard COC contraindications, including history of VTE, smoking in women >35 years, uncontrolled hypertension, or migraine with aura 3

The Centers for Disease Control and Prevention recommends starting COCs on Day 1 of the menstrual cycle for immediate contraceptive protection, and using backup contraception for 7 days if started later than Day 5 4
The American College of Obstetricians and Gynecologists suggests taking one active tablet daily for 24 consecutive days, followed by 4 placebo tablets, and taking at the same time each day, preferably after evening meal or at bedtime 4
The American Academy of Pediatrics suggests considering an 84/7 extended cycle regimen (84 active pills, 7 placebo pills) to reduce menstrual periods to 4 per year, or increasing the estrogen dose to 30-35μg EE formulation if breakthrough bleeding persists with 20μg EE 5

The Centers for Disease Control and Prevention recommends reassuring patients that breakthrough bleeding typically improves with continued use, and considering NSAIDs for 5-7 days during bleeding episodes for persistent heavy or prolonged bleeding 3
If bleeding persists beyond 3 cycles, the Centers for Disease Control and Prevention suggests considering switching to a different formulation, and evaluating for underlying gynecologic problems such as fibroids, polyps, or endometriosis before attributing heavy bleeding to hormonal causes 4
The American Academy of Pediatrics recommends considering norethindrone or norgestimate-containing COCs if side effects from drospirenone occur 5

If estrogen is contraindicated, non-hormonal alternatives like low-dose paroxetine, venlafaxine, or gabapentin may be considered for vasomotor symptoms, and non-hormonal vaginal moisturizers may be beneficial for vaginal symptoms 1